Since chemotherapy is the standard treatment in triple-negative early breast cancer, when considering the plausible cause of elevated IL-17A level during adjuvant treatment, it should be kept in mind that chemotherapy causes tissue injury that is commonly accompanied by inflammation (37). Here, IL17A is linked to breast cancer.